Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Jacqueline Madison¹ and Jason Knight ¹, ¹University of Michigan, Ann Arbor
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 130 • 2019 ACR/ARP Annual Meeting
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies. The…
Abstract Number: 1788 • 2019 ACR/ARP Annual Meeting
Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome
Yu Zuo¹, Srilakshmi Yalavarthi ², Kelsey Gockman ², David Karp ³, Quan-Zhen Li ⁴ and Jason Knight ⁵, ¹University of Texas Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³UTSouthwestern Medical Center, Dallas, TX, ⁴Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic tangles of chromatin and microbicidal proteins ejected from neutrophils in response to a variety of stimuli. In antiphospholipid…
Abstract Number: 131 • 2019 ACR/ARP Annual Meeting
Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC. Some have suggested a clinically useful role for aPS-PT as a…
Abstract Number: 1791 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Elena Gkrouzman¹, Ecem Sevim ², Jackie Finik ³, Danieli Andrade ⁴, Vittorio Pengo ⁵, Savino Sciascia ⁶, Maria Tektonidou ⁷, Amaia Ugarte ⁸, Cecilia Chighizola ⁹, H Michael Belmont ¹⁰, Laura Pérez Sánchez ¹¹, Lanlan Ji ¹², Paul Fortin ¹³, Maria Efthymiou ¹⁴, Guilherme De Jesus ¹⁵, David Branch ¹⁶, Cecilia Nalli ¹⁷, Michelle Petri ¹⁸, Ricard Cervera ¹⁹, Esther Rodriguez ²⁰, Jason Knight ²¹, Tatsuya Atsumi ²², Rohan Willis ²³, Maria Laura Bertolaccini ²⁴, Hannah Cohen ¹⁴, Jacob Rand ²⁵, Doruk Erkan ¹ and On Behalf Of APS ACTION ²⁶, ¹Hospital for Special Surgery, New York City, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, New York, NY, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁵Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁷First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, ⁹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ¹⁰NYU Langone Health, New York, NY, ¹¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²²Hokkaido University, Sapporo, Japan, ²³Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵Weill Cornell Medicine, New York, ²⁶APS ACTION, New York, NY
Background/Purpose: APS ACTION "Registry" was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune diseases. Our primary…
Abstract Number: 132 • 2019 ACR/ARP Annual Meeting
Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Alejandro Ibañez-Costa ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Lourdes Alacaide-Ruggiero ⁵, Rafaela Ortega ¹, Nuria Barbarroja ⁶, Eduardo Collantes-Estevez ⁴, Massimo Radin ⁷, Irene Cecchi ⁷, Savino Sciascia ⁸ and Carlos Perez-Sanchez ⁹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba, Cordoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The clinical significance of non-canonical anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS) is still controversial. This study assessed the prevalence of aPS/PT antibodies, their association with…
Abstract Number: 1793 • 2019 ACR/ARP Annual Meeting
Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Maxime Taghavi¹, Medha Barbhaiya ², Maria Tektonidou ³, Paul Fortin ⁴, Danieli Andrade ⁵, Jason Knight ⁶, Bahar Artim-Esen ⁷, Tatsuya Atsumi ⁸, Hannah Cohen ⁹, Lanlan Ji ¹⁰, Savino Sciascia ¹¹, Surya Seshan ¹², Doruk Erkan ¹³ and on Behalf of APS ACTION ¹⁴, ¹Brugmann Hospital, Brugmann, Belgium, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁵Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁷Istanbul University School of Medicine, Istanbul, Turkey, ⁸Hokkaido University, Sapporo, Japan, ⁹University College London, London, United Kingdom, ¹⁰Peking University First Hospital, Beijing, China (People's Republic), ¹¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ¹²Weill Cornell Medicine, New York, ¹³Hospital for Special Surgery, New York City, ¹⁴Hospital for Special Surgery, New York
Background/Purpose: Antiphospholipid antibody (aPL) nephropathy is a distinct entity that can be challenging to recognize and treat; it remains unknown if uniform pathologic criteria are…
Abstract Number: 135 • 2019 ACR/ARP Annual Meeting
Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations
Savino Sciascia¹, Irene Cecchi ², Massimo Radin ², Elena Rubini ², Silvia Grazietta Foddai ², Dario Roccatello ², Chelsea Bentow ³, Andrea Seaman ³, Carlos Ramirez ³ and Michael Mahler ³, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³Inova Diagnostics, San Diego, CA
Background/Purpose: The laboratory diagnostics of antiphospholipid syndrome (APS) takes into account the persistent positivity for anticardiolipin (aCL) and/or anti-β2glycoprotein I (anti-β2GPI) antibodies and/or the presence…
Abstract Number: 1962 • 2019 ACR/ARP Annual Meeting
Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs
Markos Patsouras ¹, Panagiota Karagianni ¹, Marios Agelopoulos ², Spyros Foutadakis ², Eirini Alexopoulou ² and Panagiotis Vlachoyiannopoulos³, ¹Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece, Athens, ²Biomedical Research Foundation, Academy of Athens, ATHENS, ³University General Hospital of Athens “Laiko”, Athens, Greece
Background/Purpose: Antiphospholipid syndrome is an autoimmune thrombophillia characterized by recurrent thromboembolism and or pregrancy morbidity in the presence of antiphospholipid antibodies (aPL), which recognize either…
Abstract Number: 136 • 2019 ACR/ARP Annual Meeting
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Savino Sciascia¹, Massimo Radin ², Irene Cecchi ², Maria Laura Bertolaccini ³, Tiziana Bertero ², Elena Rubini ², Antonella Vaccarino ², Mario Bazzan ², Osvaldo Giachino ², Simone Baldovino ², Daniela Rossi ², Giulio Mengozzi ² and Dario Roccatello ², ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom
Background/Purpose: In this study, we sought to perform an unsupervised hierarchical clustering analysis in a large cohort of antiphospholipid antibodies (aPL) positive patients, to identify…
Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Michelle Petri¹, Laurence Magder ² and Daniel Goldman ³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…
Abstract Number: 137 • 2019 ACR/ARP Annual Meeting
The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Diane Zisa ², Danieli Andrade ³, Vittorio Pengo ⁴, Savino Sciascia ⁵, Maria Tektonidou ⁶, Amaia Ugarte ⁷, Maria Gerosa ⁸, H Michael Belmont ⁹, Rosario Lopez Pedrera ¹⁰, Lanlan Ji ¹¹, Paul Fortin ¹², Maria Efthymiou ¹³, Guilherme De Jesus ¹⁴, David Branch ¹⁵, Laura Andreoli ¹⁶, Michelle Petri ¹⁷, Ricard Cervera ¹⁸, Esther Rodriguez ¹⁹, Jason Knight ²⁰, Tatsuya Atsumi ²¹, Rohan Willis ²², Maria Laura Bertolaccini ²³, Hannah Cohen ¹³, Robert Roubey ²⁴, Doruk Erkan ²⁵, Medha Barbhaiya ² and on Behalf of APS ACTION ²⁶, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁴Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁶First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, ⁸Istituto Ortopedico Gaetano Pini, University of Milan, Milan, Italy, ⁹NYU Langone Health, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Cordoba, Cordoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹³University College London, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²¹Hokkaido University, Sapporo, Japan, ²²Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, ²³King's College London, London, United Kingdom, ²⁴The University of North Carolina at Chapel Hill, Chapel Hill, NC, ²⁵Hospital for Special Surgery, New York City, ²⁶APS ACTION, New York, NY
Background/Purpose: APS ACTION “Registry” was created to study the long-term natural history and outcomes of persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic…
Abstract Number: 138 • 2019 ACR/ARP Annual Meeting
Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome
Tomás Urrego ¹, Beatriz Frade-Sosa ², Alejandro Hernández ³, Sebastian Ruiz ³, Carolina Rua ⁴, Julieta Duque ⁴, Adriana Vanegas-García ⁵, Carlos H Muñoz-Vahos ⁵, Luis A González ⁵, Gloria Vasquez ⁶ and Jose A Gómez-Puerta², ¹Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Antioquia, Colombia, ²Rheumatology Department, Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Departamento de Medicina Interna, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁴Grupo de Investigación en Trombosis, Medellín, Antioquia, Colombia, ⁵Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁶University of Antioquia, Medellin, Antioquia, Colombia
Background/Purpose: Recurrent thrombosis is an uncommon complication of patients with antiphospholipid syndrome (APS), usually related with persistent high levels of antiphospholipid antibodies (aPL), specially classic aPL…
Abstract Number: 140 • 2019 ACR/ARP Annual Meeting
Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis
Hanxiao You¹, Jiuliang Zhao ², Xinping Tian ², Mengtao Li ³ and Xiaofeng Zeng ², ¹Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic)
Background/Purpose: Portal vein thrombosis (PVT) is a rare and severe clinical phenotype of antiphospholipid syndrome (APS) with a poor prognosis. Anticoagulation therapy is efficient, but is associated with potentially…
Abstract Number: 142 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities
Silvia Grazietta Foddai¹, Massimo Radin ¹, Elena Rubini ¹, Irene Cecchi ¹, Savino Sciascia ², Dario Roccatello ¹, Elisa Menegatti ¹, Silvia Gaito ¹, Luca Marozio ¹, Tilde Manetta ¹ and Giulio Mengozzi ¹, ¹University of Turin, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: While current guidelines help defining correct pregnancy standard of care for patients with systemic lupus erythematosus andantiphospholipid syndrome (APS),little is known about the significance…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.